Flutamide versus stilboestrol in the management of advanced prostatic cancer. A controlled prospective study.
In a prospective randomised study the effect of flutamide 750 mg daily was compared with that of stilboestrol 3 mg daily in the treatment of 40 previously untreated patients with advanced prostatic cancer. There was a good subjective response to both treatments. After 12 months, a response was demonstrated in 13 of 20 patients treated with flutamide and 8 of 20 patients treated with stilboestrol. The difference was not statistically significant. Treatment with stilboestrol caused more frequent, and more severe, side effects than flutamide.
Lund
F
F
Department of Urology, Rigshospital, University of Copenhagen, Denmark.
Rasmussen
F
F
D000368:Aged; D000369:Aged, 80 and over; D000813:Anilides / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004054:Diethylstilbestrol / Q000627:therapeutic use*; D005485:Flutamide / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D011897:Random Allocation; D013739:Testosterone / Q000097:blood
D000813:Anilides; D013739:Testosterone; D004054:Diethylstilbestrol; D005485:Flutamide